Skye reports Q4 loss $14.4M, cash $25.7M; initiates higher-dose CBeyond study after 22.3% weight loss at 52 weeks

Skye Bioscience, Inc.

Net loss Q4 2025: $14.4M; full year $55.9M; cash & equivalents $25.7M as of Dec 31, 2025.
Interim 52-week data: nimacimab+semaglutide achieved 22.3% mean weight loss; no plateau observed.
Initiated CBeyond Expansion Study: higher doses (400 mg and 600 mg IV) vs placebo; topline Q4 2026.
Weight regain during 13-week off-treatment: combo cohort regained 17.8% vs 37.3% for semaglutide alone.
FDA Type C meeting completed; feedback informing Phase 2b design including potential add-on with incretin.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Skye Bioscience, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.

Period: the fourth quarter and full year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 10, 2026 , Skye Bioscience, Inc. (the “Company” or “Skye”) issued a press release reporting its financial results for the fourth quarter and full year ended December 31, 2025.

View on SEC.gov

Browse all earnings releases →

Skye Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-016400

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.